FDA Clearance Tracker · P190002-S019
Saluda Medical Evoke® SCS System
Last checked: Nov 20, 2026Latest source record: Mar 20, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Mar 20, 2024
Approved
Time to decision
180 days
Received Sep 22, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P190002-S019
- Device name
- Saluda Medical Evoke® SCS System
- Applicant
- Saluda Medical Pty, Ltd.
- Applicant location
- Atarmon
- Received
- Sep 22, 2023
- Decided
- Mar 20, 2024
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P190002
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for expanding the indications to include diabetic peripheral neuropathy of the lower extremities
Source documents
Other decisions for Saluda Medical Pty, Ltd.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P190002 · Decided Feb 28, 2022 · 1,133 days after receipt
Device type: Stimulator, spinal-cord, totally implanted for pain relief (LGW) · Neurology & Neurosurgery
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.